ArticleBriefings in bioinformatics2026
Enhancing cancer classification accuracy with a self-attention network using panel capture sequencing data.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cancer classification is pivotal for precision oncology, yet traditional methods struggle with the molecular heterogeneity of tumors. Our study introduces a self-attention based Conv1D machine learning network designed for panel capture sequencing data, which is more commonly used in clinical settings. Combining clinical capture sequencing data and The Cancer Genome Atlas data, we achieved an overall classification accuracy of over 90%, with precision rates reaching 100% for cervical and gastric cancers. Additionally, recall rates were highest at 95.79% for gastric cancer and lowest at 77.46% for cervical cancer, demonstrating robust performance across various cancer types. The model identified key genes such as C3orf36, JHY, and TASP1, showing significant differences in mutation counts across cancers. High-impact gene enrichment analysis highlighted critical pathways like acute myeloid leukemia and adipocytokine signaling. This approach not only significantly improves the precision of cancer classification, demonstrating the potential for clinical application, but also enhances our understanding of cancer biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.